证券代码：688293 证券简称：奥浦迈 公告编号：2023-031 上海奥浦迈生物科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）于2023年 8月29日召开第一届董事会第十七次会议、第一届监事会第十三次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在保证不影 响募集资金投资项目实施、确保募集资金安全的前提下，使用最高不超过人民币 90,000.00万元（包含本数）暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好的投资产品（包括但不限于协定性存款、结构性存款、定期存款、通知 存款、大额存单等），在上述额度范围内，资金可以滚动使用，使用期限为12 个月。同时董事会授权公司管理层行使现金管理投资决策权并签署相关合同/协 议文件，具体事项由公司财务部负责组织实施。公司独立董事、监事会发表了明 确同意的意见，保荐机构海通证券股份有限公司（以下简称"海通证券"或"保荐 机 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票首次授予日：2023 年 8 月 30 日； 限制性股票首次授予数量：70.80 万股，占公司股本总额 114,772,460 股 的 0.62%； 证券代码：688293 证券简称：奥浦迈 公告编号：2023-033 上海奥浦迈生物科技股份有限公司 关于公司 2023 年限制性股票激励计划向激励对象首 次授予限制性股票的公告 股权激励方式：第二类限制性股票。 《上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划》（以下简 称"本激励计划"或"《激励计划》"）规定的上海奥浦迈生物科技股份有限公司 （以下简称"公司"或"本公司"或"奥浦迈"）2023 年限制性股票激励计划授 予条件已经成就，根据公司 2023 年第二次临时股东大会授权，公司于 2023 年 8 月 29 日召开第一届董事会第十七次会议、第一届监事会第十三次会议，审议通 过了《关于公司 2023 年限制性股票激励计划向激励对象首次授予限制性股票的 议案》，确定本激励计划首次授 ...

北京荣大商务有限公司 关于 上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划 首次授予相关事项 之 独立财务顾问报告 二〇二三年八月 独立财务顾问报告 北京荣大商务有限公司 目 录 | 一、释义 . | | --- | | 二、声明 . | | 三、基本假设 3 | | 四、本激励计划已履行的审批程序 | | 五、本激励计划首次授予条件成就情况的说明 6 | | 六、本激励计划首次授予情况 7 | | 七、结论性意见 9 | | 八、备查文件及咨询方式 10 | | (一) 备查文件 . | | （二）咨询方式…………………………………………………………………………………………………………………………………………………… 10 | 独立财务顾问报告 北京荣大商务有限公司 释义 以下词语如无特殊说明,在本文中具有如下含义: | 奥浦迈、公司、上市公司 | 指 | 上海奥浦迈生物科技股份有限公司 | | --- | --- | --- | | 独立财务顾问 | 指 | 北京荣大商务有限公司 | | 本激励计划、股权激励计 | 指 | 上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划(草 ...

海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为上海奥浦 迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开发行股票并上 市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科创 板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关规定，对公司使用部分闲置募集资金进行现金管理的事项进行了核 查，具体情况如下： 一、募集资金基本情况 本着股东利益最大化的原则，为提高公司资金使用效率，在确保不影响募集 资金投资项目建设的前提下，合理使用部分暂时闲置募集资金进行现金管理，提 高募集资金使用效率，增加资金效益，实现公司资金的保值增值，为公司和股东 获取更多回报。 根据中国证券监督管理委员会于2022年6月13日出具的《关于同意上海奥浦 迈生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕1232 号），并经上海证券交易所同意，公司首次公开发行人民币普通 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2023-028 上海奥浦迈生物科技股份有限公司 第一届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第一届董 事会第十七次会议于2023年8月29日通过现场表决与通讯相结合的方式召开。本 次会议通知及相关资料已于2023年8月20日送达全体董事。本次会议由董事长肖 志华先生召集并主持，会议应出席董事9名，实际出席董事9名，本次会议的召集、 召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 表决结果：同意9票，反对0票，获全体董事一致通过。 1、审议通过了《关于公司<2023年半年度报告及其摘要>的议案》 董事会对公司2023年半年度报告及其摘要进行审核并发表书面意见，董事会 认为： （1）公司严格按照各项法律法规、规章制度等的要求规范运作，公司2 ...

优 化 ，成就与众不同 Optimization Makes Differences 上海奥浦迈生物科技股份有限公司独立董事 关于公司第一届董事会第十七次会议 相关议案的独立意见 根据中国证监会《上市公司独立董事规则》《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《科创板股票上市规则》"）及《上海奥浦迈生物科技股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，我们作为上海奥浦迈生物科技股份有限公司 （以下简称"公司"或"奥浦迈"）的独立董事，本着对公司及全体股东负责的 态度，基于独立、客观、审慎的原则，现就公司第一届董事会第十七次会议审议 的相关事项发表独立意见如下： 一、关于《关于<公司 2023 年半年度募集资金实际存放与使用情况的专项 报告>的议案》的独立意见 我们认为：公司 2023 年半年度募集资金实际存放与使用情况符合中国证监 会、上海证券交易所关于上市公司募集资金存放与使用的相关规定，不存在违反 募集资金管理和使用的相关规定，不存在损害公司及股东，特别是中小股东利益 的情形；公司董事会编制的《公司 2023 年半年度募集资 ...

上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股及部分战略配售限售股上 市流通公告 证券代码：688293 证券简称：奥浦迈 公告编号：2023-027 海证券交易所同意，公司首次向社会公众公开发行人民币普通股2,049.5082万股， 并于2022年9月2日在上海证券交易所科创板上市。公司首次公开发行完成后总股 本为8,198.0328万股，其中，有限售条件流通股6,505.5766万股，占公司总股本的 79.36%，无限售条件流通股为1,692.4562万股，占公司总股本的20.64%。 本次上市流通的限售股为公司首次公开发行部分限售股及部分战略配售股 份，涉及限售股股东数量为9名，限售期为自公司股票上市之日起12个月，具体 详见公司于2022年8月30日在上海证券交易所网站（www.sse.com.cn）披露的《上 海奥浦迈生物科技股份有限公司首次公开发行股票并在科创板上市发行结果公 告》。本次解除限售的股份数量为50,729,865股，占公司股本总数的44.20%，其 中，战略配售股份数量为2,869,311股，占公司股份总数的2.50%；除战略配售股 份外，本次上市流通的限售股数量为47,86 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2023-017 上海奥浦迈生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023年6月7日（星期三）下午13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2023年05月31日(星期三)至06月06日(星期二)16:00前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@opmbiosciences.com进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）已分别于 2023年3月30日发布公司《2022年年度报告》、2023年4月28 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 67,917,690.55, representing a decrease of 6.53% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 24,191,151.59, down by 4.26% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 21,054,676.90, reflecting an 11.50% decline compared to the previous year[5]. - In Q1 2023, the total revenue was CNY 67,917,690.55, a decrease of 6.5% compared to CNY 72,665,072.90 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 24,065,980.32, compared to CNY 25,268,632.49 in Q1 2022, indicating a decline of 4.8%[25]. - The net profit attributable to the parent company for Q1 2023 is CNY 24,191,151.59, a decrease of 4.3% compared to CNY 25,268,632.49 in Q1 2022[26]. - The basic and diluted earnings per share for Q1 2023 are CNY 0.30, down from CNY 0.41 in Q1 2022, representing a decline of 26.8%[26]. Cash Flow - The net cash flow from operating activities increased significantly by 90.86%, amounting to CNY 4,496,312.41[5]. - Cash inflow from operating activities for Q1 2023 is CNY 64,579,092.78, an increase of 21.0% from CNY 53,366,977.29 in Q1 2022[28]. - The net cash flow from operating activities for Q1 2023 is CNY 4,496,312.41, up from CNY 2,355,851.35 in Q1 2022, indicating a growth of 90.9%[28]. - Cash outflow from investing activities in Q1 2023 is CNY 361,891,423.70, significantly higher than CNY 25,022,935.96 in Q1 2022[29]. - The net cash flow from investing activities for Q1 2023 is -CNY 90,260,145.10, compared to -CNY 24,322,935.96 in Q1 2022, reflecting a deterioration in investment cash flow[29]. - The net cash flow from financing activities for Q1 2023 is -CNY 3,123,849.50, an improvement from -CNY 5,992,187.60 in Q1 2022[29]. - The total cash and cash equivalents at the end of Q1 2023 is CNY 1,416,319,230.30, compared to CNY 275,189,112.45 at the end of Q1 2022, showing a substantial increase[29]. - The company's cash and cash equivalents decreased to CNY 1,416,319,230.30 as of March 31, 2023, from CNY 1,505,906,562.65 at the end of 2022, a drop of 5.9%[21]. Research and Development - Research and development expenses totaled CNY 9,727,974.76, an increase of 81.11%, accounting for 14.32% of operating revenue, which is an increase of 6.93 percentage points[5]. - The company's R&D investment totaled 9.73 million RMB, accounting for 14.32% of revenue, representing an increase of 81.11% year-over-year[17]. - R&D expenses increased to CNY 9,727,974.76 in Q1 2023, up from CNY 5,371,286.68 in Q1 2022, representing an increase of 80.5%[25]. - As of the end of Q1 2023, the company had 125 confirmed drug development pipelines using its cell culture products, an increase of 14 from the end of 2022[17]. - Among the 125 pipelines, 72 are in the preclinical stage, 25 in Phase I, 10 in Phase II, 17 in Phase III, and 1 in commercial production[18]. Operational Efficiency - The company has strengthened internal management and improved operational efficiency in response to challenges in the biopharmaceutical industry[16]. - The gross profit margin remained high, improving by approximately 1 percentage point compared to the same period last year[16]. - The revenue from cell culture media significantly increased, demonstrating strong resilience in the high-end culture media sector[16]. - The company signed a strategic research cooperation agreement with East China University of Science and Technology in November 2022, establishing a joint research institute[17]. - The company plans to expand its market presence and has resumed some projects that were previously delayed due to adverse market conditions[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,352,102,249.90, a slight increase of 0.19% from the end of the previous year[5]. - The total assets as of March 31, 2023, were CNY 2,352,102,249.90, slightly up from CNY 2,347,749,143.04 at the end of 2022[22]. - The company's total liabilities decreased to CNY 142,562,885.63 as of March 31, 2023, from CNY 163,071,138.95 at the end of 2022, a reduction of 12.5%[23]. - The company reported an increase in accounts receivable to CNY 77,863,525.60 as of March 31, 2023, compared to CNY 75,869,111.97 at the end of 2022, an increase of 2.6%[21]. - The company reported a significant increase in accounts receivable by 126.35%, primarily due to an increase in bank acceptance bills received[8]. Strategic Developments - The company is currently constructing a CDMO biopharmaceutical commercialization production platform, expected to enhance service capabilities significantly upon completion in H1 2023[19]. - The company's major IVD clients had temporarily increased their procurement of culture media in Q1 2022, which affected the year-over-year comparison[16]. - The company did not execute any mergers or acquisitions during the reporting period[26]. - The actual controllers of the company hold a combined 31.49% of the shares, with 24.41% directly held by the main shareholder[14].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 25% growth compared to the previous year[15]. - The company's operating revenue for 2022 was CNY 294,365,734.14, representing a 38.41% increase compared to CNY 212,683,302.44 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 105,369,365.72, a significant increase of 74.47% from CNY 60,393,665.20 in 2021[25]. - The net profit after deducting non-recurring gains and losses was CNY 88,797,877.12, up 79.23% from CNY 49,543,382.24 in the previous year[25]. - The company's total assets reached CNY 2,347,749,143.04 at the end of 2022, a 214.26% increase from CNY 747,078,076.82 at the end of 2021[25]. - The net assets attributable to shareholders increased by 288.42% to CNY 2,184,678,004.09 from CNY 562,453,622.16 in 2021[25]. - The company's operating profit reached 115.92 million yuan, up 80.54% year-on-year[132]. - The overall gross margin for the reporting period was 63.97%, with the gross margin for the CDMO business at 40.99%[121]. Dividends and Capital Structure - The company plans to distribute a cash dividend of RMB 6.00 per 10 shares, totaling approximately RMB 49.19 million, which represents 46.68% of the net profit attributable to shareholders for 2022[6]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in a total increase of 32,792,132 shares, raising the total share capital from 81,980,328 to 114,772,460 shares[6]. Governance and Compliance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[5]. - The company has not violated any decision-making procedures in providing guarantees to external parties[8]. - The company has not disclosed any special arrangements in corporate governance[8]. - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and coordinated operations[181]. - The company has ensured compliance with legal and regulatory requirements in its decision-making processes[181]. Research and Development - The R&D expenditure as a percentage of operating revenue was 11.28%, up 2.02 percentage points from 9.26% in 2021[26]. - The total R&D investment for the reporting period reached ¥33,195,981.13, representing a 68.60% increase compared to the previous year, and accounting for 11.28% of total revenue[91][92]. - The number of R&D personnel increased from 34 to 52, with the proportion of R&D staff in the total workforce rising from 16.35% to 19.92%[94]. - The company has developed proprietary technologies that allow precise control of culture medium components, enhancing product expression levels[82]. - The company has developed several new cell culture media products, including StarCHO and SagiCHO series, which significantly enhance cell growth and protein expression compared to imported media[86]. Market Expansion and Strategy - The company is expanding its market presence by entering two new international markets, aiming for a 15% market share within the first year[15]. - The company aims to enhance its clinical research capabilities, with plans to initiate Phase II clinical trials for its lead drug candidate in Q4 2023[15]. - The company is focused on expanding its overseas market presence to promote its cell culture products and CDMO services internationally[86]. - The company plans to establish two 500L and two 2,000L antibody production lines in its D3 CDMO factory in 2023, significantly enhancing CDMO service capacity[173]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the stability of raw material supply, with a reliance on a few core suppliers for critical components of its media products[114]. - The company is at risk of potential technology leaks or intellectual property issues, which could adversely affect its core competitiveness[110]. - The company faces risks related to potential contract terminations or payment delays in its CDMO business due to uncertainties in drug research outcomes and market conditions[120]. Customer and Market Engagement - User data showed a 30% increase in the number of active users, reaching 500,000 by the end of the year[15]. - The company has served over 600 domestic and international biopharmaceutical enterprises and research institutions, with a total of 111 drug development pipelines using its cell culture products, an increase of 50.00% from the end of 2021[38]. - The company has established a new partnership with a leading healthcare provider, expected to drive further growth in user acquisition[191]. Financial Health and Investments - The company's cash and cash equivalents increased to 1,202,710,345.67 RMB, primarily due to funds raised from the initial public offering[152]. - The total assets increased significantly, with cash and cash equivalents accounting for 64.14% of total assets, up from 41.54% in the previous year[153]. - The company has a robust procurement system, ensuring stable supply by selecting multiple qualified suppliers for critical raw materials[65]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.44 billion RMB[15]. - The company plans to invest 100 million RMB in upgrading its manufacturing facilities to meet GMP standards by the end of 2023[15]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[186].